Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 21, 2009

Preliminary Phase III Data Is Positive for Novartis’ COPD Drug

  • Initial results from Phase III trials of Novartis’ bronchodilator candidate suggest the drug significantly improves lung function in patients with chronic obstructive pulmonary disease (COPD) compared with formoterol and tiotropium. The compound is currently under regulatory review in the EU and U.S.

    These findings board well not only for approval of QAB149 but also for development of the compound in combination with other therapies. Just 48 hours ago Novartis amended its deal with Schering-Plough to obtain exclusive, worldwide development and marketing rights to such a combination therapy, which is already in Phase II. CMF149 is a fixed-dose combination of QAB149 and Schering-Plough’s inhaled corticosteroid, mometasone furoate.

    Initial evaluations of QAB149 found that significant improvements in patients’ lung function were evident within five minutes of first dosing with the long-acting beta2 agonist and lasted for 24 hours. Improvements were seen from the first day of treatment, up to one year. The findings were presented at the American Thoracic Society 2009 International Conference, in San Diego.



Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »